2
https://laptopsuggestions.in/sanofis-dupixent-scores-nice-recommendation-after-price-cut/
When the U.K.'s cost effectiveness watchdogs at NICE reviewed Sanofi's blockbuster hopeful Dupixent earlier this year, they concluded that the drug was an advance for atopic dermatitis patients, but too expensive to justify for coverage. Now, they've given it a blessing contingent on a confidential discount.